Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Abstract Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	Wiley 2019-10-01
Σειρά:	Cancer Medicine
Θέματα:	anaplastic lymphoma kinase inhibitor crizotinib crizotinib continuation beyond progressive disease non‐small cell lung cancer treatment duration
Διαθέσιμο Online:	https://doi.org/10.1002/cam4.2420

Παρόμοια τεκμήρια

Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
ανά: Carolina Valeria Mahuad, κ.ά.
Έκδοση: (2016-06-01)

Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC
ανά: Emei GAO, κ.ά.
Έκδοση: (2016-03-01)

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
ανά: Ahmed Badran, κ.ά.
Έκδοση: (2023-08-01)

Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer  after Resistance to Crizotinib
ανά: Tao JIANG, κ.ά.
Έκδοση: (2015-02-01)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
ανά: Moushumi Suryavanshi, κ.ά.
Έκδοση: (2017-01-01)

Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase‐positive non–small cell lung cancer
ανά: Xiya Ma, κ.ά.
Έκδοση: (2022-06-01)

Crizotinib in treatment of lung cancer
ανά: Arpita Singh, κ.ά.
Έκδοση: (2017-01-01)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
ανά: Dennis Christoph Harrer, κ.ά.
Έκδοση: (2020-10-01)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
ανά: Yuka Kuriyama, κ.ά.
Έκδοση: (2013-08-01)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
ανά: Caiyu Lin, κ.ά.
Έκδοση: (2021-12-01)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
ανά: Chang Liu, κ.ά.
Έκδοση: (2019-10-01)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
ανά: Chan-Young Ock, κ.ά.
Έκδοση: (2019-09-01)

The Dual Role of Autophagy in Crizotinib-Treated ALK<sup>+</sup> ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
ανά: Estelle Espinos, κ.ά.
Έκδοση: (2021-09-01)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
ανά: Muhammad Wasi Alam, κ.ά.
Έκδοση: (2019-07-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
ανά: Zihua Zou, κ.ά.
Έκδοση: (2022-01-01)

Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report
ανά: Henan BAI, κ.ά.
Έκδοση: (2021-08-01)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
ανά: Daijiro Harada, κ.ά.
Έκδοση: (2021-03-01)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
ανά: Scott N. Gettinger, MD, κ.ά.
Έκδοση: (2022-09-01)

Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea
ανά: Da Som Jeon, κ.ά.
Έκδοση: (2024-02-01)

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
ανά: Tomonobu Koizumi, κ.ά.
Έκδοση: (2016-04-01)

Crizotinib-Associated Renal Cysts: A Case Series
ανά: Garima Suman, κ.ά.
Έκδοση: (2019-07-01)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
ανά: Woo Kyung Ryu, κ.ά.
Έκδοση: (2022-10-01)

A Case of Orbital Metastasis as Disease Progression of Anaplastic Lymphoma Kinase-Positive Lung Cancer Treated with Crizotinib
ανά: Yoshihiko Sakata, κ.ά.
Έκδοση: (2015-01-01)

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer
ανά: Mohieldin A, κ.ά.
Έκδοση: (2018-11-01)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
ανά: Di Marino P, κ.ά.
Έκδοση: (2020-03-01)

Molecular epidemiological study of microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene using immunohistochemistry as a cost effective alternative to fluorescence in situ hybridization for Indian patients with adenocarcinoma lung
ανά: Anurag Mehta, κ.ά.
Έκδοση: (2017-01-01)

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
ανά: Ken Koshikawa, κ.ά.
Έκδοση: (2020-06-01)

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
ανά: Jun Osugi, κ.ά.
Έκδοση: (2016-01-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
ανά: Jing ZHAO, κ.ά.
Έκδοση: (2015-10-01)

Modern treatment of ALK-positive non-small cell lung cancer
ανά: D. A. Kharagezov, κ.ά.
Έκδοση: (2022-06-01)

Identification of a novel ALK variant intrinsically resistant to crizotinib
ανά: Ullas Batra, κ.ά.
Έκδοση: (2020-12-01)

Efficacy and Safety of Crizotinib in Advanced or Recurrent  ALK-positive Non-small Cell Lung Cancer
ανά: Xiaoyan LI, κ.ά.
Έκδοση: (2019-08-01)

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature
ανά: Peng Zhang, κ.ά.
Έκδοση: (2024-04-01)

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL
ανά: Wanying Liu, κ.ά.
Έκδοση: (2024-02-01)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
ανά: Yurong Wang, κ.ά.
Έκδοση: (2022-12-01)

Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer
ανά: Giacomina Megaro, κ.ά.
Έκδοση: (2022-03-01)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
ανά: Caicun Zhou, MD, PhD, κ.ά.
Έκδοση: (2024-09-01)

Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib
ανά: Yuhang Zhou, κ.ά.
Έκδοση: (2023-11-01)

Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
ανά: Julia Barbara Bargieł, κ.ά.
Έκδοση: (2021-09-01)

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
ανά: Min Zhang, MBBS, κ.ά.
Έκδοση: (2021-02-01)